Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07216508 · ClinicalTrials.gov registry record
Liver Transplant CGM
A clinical trial of Type 2 Diabetes and Liver Transplant, sponsored by Icahn School of Medicine at Mount Sinai.
- Recruiting
- Registry status
- 40
- Enrollment target
- 1
- Study location
NCT07216508 is a study of Type 2 Diabetes and Liver Transplant that is actively recruiting participants, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 40 participants, below the 1,102-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07216508, a study of Type 2 Diabetes and Liver Transplant, is actively recruiting participants, sponsored by Icahn School of Medicine at Mount Sinai.
- RECRUITING
- Registry status
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
This investigator initiated study aims to describe continuous glucose monitoring (CGM) based glycemic metrics after discharge from liver transplant and assess relationship with glycemic metrics and liver transplant outcomes.
Conditions Studied
Interventions
- DEVICE Libre 3+
Study Locations (1)
New York
- Mount Sinai Hospital - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2025-10-13 |
| Est. Completion | 2027-10-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07216508
The ClinicalTrials.gov registry entry for NCT07216508 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,102-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (96% lower). The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Type 2 Diabetes appearing as the primary indexed condition, and to 1 intervention - of which Libre 3+ is the first listed.
NCT07216508 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT07216508 about?
NCT07216508 is a clinical study titled "Liver Transplant CGM". This investigator initiated study aims to describe continuous glucose monitoring (CGM) based glycemic metrics after discharge from liver transplant and assess relationship with glycemic metrics and liver transplant outcomes.
What is the current status of trial NCT07216508?
This trial is currently recruiting. The enrollment target is 40 participants. The study started on 2025-10-13. Estimated completion is 2027-10-05.
What conditions does trial NCT07216508 study?
This clinical trial studies the following conditions: Type 2 Diabetes, Liver Transplant, Post Transplant Diabetes.
What interventions are being tested in trial NCT07216508?
The interventions under investigation include: Libre 3+ (DEVICE).
Who is sponsoring clinical trial NCT07216508?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07216508 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Enhancing Telemedicine for T2D
RECRUITING · NA
-
Sleep and Glycemic Control in Type 2 Diabetes Adolescents
RECRUITING · NA
-
Enhancing Preventative Health Behaviors Among Emergency Department Hyperglycemic Patients
RECRUITING · NA
-
Ultrasound Effects on Glycemic Control in T2DM
RECRUITING · NA
-
Mechanism of SGLT2 Inhibition in the Kidney
RECRUITING · Phase 4
-
Acute and Chronic Effects of Oral Ketones in Subjects With HFrEF and Diabetes
RECRUITING · Early Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.